- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02145377
PXVX0200 (CVD103-HgR) vs Shanchol in Mali
A Phase 2 Randomized, Double-Blinded Study to Compare in Malian Adults the Immunogenicity, Clinical Acceptability and Excretion Pattern Following the Ingestion of a Single Dose of PXVX0200 (CVD 103-HgR) Live Oral Cholera Vaccine Containing Either 108 Colony Forming Units [Cfu] or 109 Cfu Using Shanchol™ Killed Whole Cell Oral Cholera Vaccine as an Immunological Comparator
To compare the ability of a single dose of PXVX0200 at two different dose levels, to placebo to elicit a significant antibody response 14 days after vaccination, compared to baseline.
To compare the ability of a single dose of PXVX0200 to a comparator vaccine Shanchol, a two dose administration, to elicit antibody response by 14 days after vaccination.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Currently there are two licensed inactivated vibrio oral vaccines (Dukoral® [Crucell; Leiden, The Netherlands] and Shanchol™ [Shantha Biotechnics; Hyderabad, India]) that are pre-qualified by the World Health Organization (WHO) for procurement by United Nations (UN) agencies. Each of these vaccines requires a two-dose regimen which is difficult to implement in the face of explosive outbreaks of cholera in unsettled situations in developing countries. For this reason there is great interest in identifying a cholera vaccine that can provide rapid onset of protection following the ingestion of just a single oral dose.
This Phase 2 randomized, observer-blinded and subject-blinded clinical trial to be conducted in Bamako, Mali will assess the immunogenicity of the 10^8 cfu versus the 10^9 cfu formulation of PaxVax-manufactured CVD 103-HgR.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Bamako, Mali
- Centre pour le Développement des Vaccins, Mali (CVD-Mali)
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Able to understand the study and give consent (either written or through a process that involves audio tapes explaining all aspects of the study and the consent form in local languages [Bambara and French] followed by making a mark and signature by a literate witness)
- Healthy men or women, age 18 to 45 years (inclusive) without significant medical history
- Women of child-bearing potential must have negative urine pregnancy test at baseline, prior to vaccination. They must also be willing to use adequate birth control for the duration of the 28-day study and have additional pregnancy tests if indicated. Effective methods of birth control for this study include abstinence, intrauterine device (IUD), oral or depot contraceptive, or barrier plus spermicide
- Willingness to remain in the study area until at least 42 days after receipt of the first vaccine dose
Exclusion Criteria:
- Health care workers who have direct contact with patients who are immune deficient, HIV-positive, or have an unstable medical condition
- Clinically significant history of immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurologic illness, psychiatric disorder requiring hospitalization, current drug or alcohol abuse
- History of an abnormal stool pattern or regular use of laxatives
- Previously received a licensed or investigational cholera vaccine
- History of cholera illness
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: PXVX0200 10E8 then placebo
PXVX0200 10E8 on day 0; Placebo on day 14
|
Oral dose of PXVX0200 10E8
Oral dose of sodium bicarbonate buffer
|
Experimenteel: Placebo, then PXVX0200 10E8
Placebo on day 0; PXVX0200 10E8 on day 14
|
Oral dose of PXVX0200 10E8
Oral dose of sodium bicarbonate buffer
|
Experimenteel: PXVX0200 10E9 then Placebo
PXVX0200 10E9 on day 0; Placebo on day 14
|
Oral dose of sodium bicarbonate buffer
Oral dose of PXVX0200 10E9
|
Experimenteel: Placebo then PXVX0200 10E9
Placebo on day 0; PXVX0200 10E9 on day 14
|
Oral dose of sodium bicarbonate buffer
Oral dose of PXVX0200 10E9
|
Actieve vergelijker: Shanchol
Two doses of Shanchol, on day 0 and day 14
|
Licensed comparator
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
To elicit a significant rise in serum Inaba vibriocidal antibody after a single vaccination
Tijdsspanne: 14 days
|
A comparison of the ability of a single ≥2 x10E9 cfu oral dose versus a single ≥2 x10E8 cfu oral dose of PXVX0200 (CVD 103-HgR) versus placebo to elicit a significant (> 4-fold) rise in serum Inaba vibriocidal antibody 14 days after vaccination, compared to baseline
|
14 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
To measure antibody response for a 10E8 dose and 10E9 dose of PXVX0200 oral vaccine
Tijdsspanne: 14 days
|
To compare the ability of a single ≥2 x108 cfu dose of PXVX0200 (CVD 103-HgR) or ≥2 x109 oral dose of PXVX0200 (CVD 103-HgR) versus Shanchol™ to elicit serum Inaba vibriocidal antibody mean fold rise (compared to baseline titer) and GMT
|
14 days
|
To plot the kinetics of the serum Inaba Vibriocidal antibody response
Tijdsspanne: Baseline and post-vaccination time point.
|
To plot the kinetics of the serum Inaba vibriocidal antibody response after ingestion of a single oral dose of PXVX0200 (CVD 103-HgR) containing ≥2 x10E8 cfu or ≥2 x10E9 cfu versus Shanchol™.
(With GMT on the Y axis and time points on the X axis, the GMTs at baseline and at each post-vaccination time point will be connected as a line graph).
|
Baseline and post-vaccination time point.
|
Assess fecal shedding of PXVX0200
Tijdsspanne: Day 1-3, day 7 and day 14
|
Shedding of CVD 103-HgR in stool as determined by stool culture (whole specimen or rectal swab)
|
Day 1-3, day 7 and day 14
|
Compare rate of diarrhea
Tijdsspanne: 7 days
|
To compare the rate of diarrhea (≥ 4 loose stools within 24 hours) following administration of each vaccine regimen versus placebo over 7 days of follow-up
|
7 days
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Plot seroconversion
Tijdsspanne: Day 7, 14, 21, 28, 35 and 42
|
To plot the seroconversion (≥ 4-fold increase over baseline), mean fold rise (comparing baseline titer with post-vaccination titer), and kinetics of serum IgG cholera antitoxin antibody following the ingestion of a single oral dose of PXVX0200 (CVD 103-HgR) containing ≥2 x10E8 cfu or ≥2 x10E9 cfu versus Shanchol™.
|
Day 7, 14, 21, 28, 35 and 42
|
Assess reactogenicity
Tijdsspanne: For seven days after each dose of PXVX0200
|
Assess tiredness, vomiting, loss of appetite, abdominal pain and headache
|
For seven days after each dose of PXVX0200
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Samba O Sow, MD, MS, Centre pour le Developpement des Vaccins - Mali
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HP-00059690
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Cholera
-
Bavarian NordicEmergent BioSolutionsVoltooidCholera (aandoening)Verenigde Staten
-
Johns Hopkins Bloomberg School of Public HealthBill and Melinda Gates Foundation; Meilleur Accès aux Soins de Santé (M.A. Santé)VoltooidCholera-vaccinatiereactie | Bijwerking op choleravaccinKameroen
-
International Vaccine InstituteMassachusetts General Hospital; EuBiologics Co.,LtdWervingCholera-vaccinatiereactieKorea, republiek van
-
University of Maryland, BaltimoreWervingVaccinatie tegen tyfus en/of choleraVerenigde Staten
-
Bharat Biotech International LimitedWerving
-
Bavarian NordicEmergent BioSolutionsVoltooidCholeraVerenigde Staten, Australië
-
National Institute of Allergy and Infectious Diseases...Voltooid
-
International Centre for Diarrhoeal Disease Research...MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.Voltooid
-
Sanofi Pasteur, a Sanofi CompanyVoltooidCholeraDominicaanse Republiek
Klinische onderzoeken op PXVX0200 10E8
-
Bavarian NordicEmergent BioSolutionsVoltooidCholeraVerenigde Staten, Australië
-
Bavarian NordicEmergent BioSolutionsVoltooid
-
Bavarian NordicEmergent BioSolutionsVoltooidCholeraVerenigde Staten
-
Bavarian NordicEmergent BioSolutionsVoltooidCholeraVerenigde Staten
-
Leiden University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentOnbekendBrachiale Plexus LetselNederland
-
Baylor College of MedicineM.D. Anderson Cancer Center; The Methodist Hospital Research Institute; Center...VoltooidNasofarynxcarcinoomVerenigde Staten